Good
Partially Aligned
Patient Risk:
Low
Summary
Most safety-related claims (neutropenia and severe diarrhea management, including withholding criteria and bowel obstruction) are directly supported by the provided ONIVYDE prescribing information excerpts. However, several other drug-label elements are present in the user’s claim list but are not verified against the supplied label text, creating potential gaps/unsupportedness risk outside the pasted warnings material.
Category Scores
Accurate Statements
ONIVYDE can cause severe/life-threatening neutropenia and fatal neutropenic sepsis; requires ANC-based monitoring and withholding/resumption.
Supported by Warnings and Precautions (5.1), including ANC monitoring and withholding when ANC <1500/mm3 and resume when ANC ≥1500/mm3.
ONIVYDE can cause severe/life-threatening diarrhea; do not administer in bowel obstruction; requires withholding for Grade 2–4 diarrhea and diarrhea management (loperamide for late onset; atropine for early onset).
Supported by Warnings and Precautions (5.2), including 'Do not administer... with a bowel obstruction', withholding for Grade 2–4 diarrhea, atropine for early-onset, and loperamide for late-onset; plus additional management guidance.
Unsupported Statements
Onivyde is covered by Medicare Part D prescription drug plans.
No support in the provided prescribing-information excerpts.
Coverage for Onivyde can vary depending on the specific Medicare Part D plan.
No support in the provided prescribing-information excerpts.
Onivyde is a prescription medication used to treat adults with pancreatic cancer.
Indication is not verified against the supplied label excerpts; only the warnings material was provided.
Onivyde is typically given in combination with other chemotherapy drugs such as leucovorin and fluorouracil.
Combination regimen details are not shown in the provided excerpts used for verification (only limited regimen context within Warnings tables).
The usual dose of Onivyde is 70 mg/m² administered intravenously every two weeks.
Dose value/timing is not present in the provided excerpts.
The 70 mg/m² every two weeks dose of Onivyde is administered in combination with leucovorin and fluorouracil.
Dose value and specific coadministration are not shown together in the provided excerpts.
Common side effects of Onivyde include diarrhea, fatigue, vomiting, nausea, decreased appetite, abdominal pain, and fever.
Only severe diarrhea/neutropenia are explicitly evidenced in the provided excerpts; 'common side effects' list is not supported by the supplied label text.
Serious side effects of Onivyde can include severe diarrhea.
Severe diarrhea risk is supported, but the statement is redundant/overbroad compared to the provided excerpt; however, the core element (severe/life-threatening diarrhea) is supported. Marked unsupported only if claiming 'serious side effects' as a general list item not evidenced.
Serious side effects of Onivyde can include hypersensitivity reactions.
The provided excerpts mention hypersensitivity in section cross-references but do not include the actual severe hypersensitivity reaction details; thus not verified.
Other chemotherapy regimens used to treat pancreatic cancer often include fluorouracil, leucovorin, irinotecan, and oxaliplatin.
Not supported by the provided label excerpts.
Onivyde is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy.
Indication text is not present in the provided excerpts.
The safety and effectiveness of Onivyde have not been established in pediatric patients.
Pediatric section is not provided in the excerpts.
Onivyde is administered as an intravenous infusion by a healthcare professional.
Administration instructions are not provided in the excerpts sufficient to confirm this phrasing.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
For neutropenia/diarrhea management claims, the AI does not include all label-required details (e.g., specific monitoring days, loperamide initiation guidance beyond late-onset, local guidelines for diarrhea not improving within 48 hours, and dose reduction specifics).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only fully verified statements concern core boxed-warning-adjacent safety topics from the provided label text (severe neutropenia/neutropenic sepsis and severe diarrhea/bowel obstruction/withholding and management). Other claims in the list are not verifiable from the supplied excerpts, but no direct label contradictions were identified from the provided material.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several non-warnings claims (indication, dosing, common side effects, pediatric statement, administration phrasing) are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Limit assertions to label sections present in the supplied text for verification, or provide/quote the relevant label sections (Indications, Dosage and Administration, Adverse Reactions, Pediatric Use, and Administration/Infusion instructions) before making those claims.